Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy.

Burnett, William J; Burnett, David M; Parkman, Gennie; Ramstead, Andrew; Contreras, Nico; Gravley, William; Holmen, Sheri L; Williams, Matthew A; VanBrocklin, Matthew W

Burnett, William J; Burnett, David M; Parkman, Gennie; Ramstead, Andrew; Contreras, Nico; Gravley, William; Holmen, Sheri L; Williams, Matthew A; VanBrocklin, Matthew W.

Afiliación

Burnett WJ; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Burnett DM; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Parkman G; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Ramstead A; Department of Pathology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Contreras N; Department of Pathology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Gravley W; School of Medicine, University of Nevada Las Vegas, Las Vegas, NV 89154, USA.
Holmen SL; Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Williams MA; Department of Pathology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
VanBrocklin MW; Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.

Cancers (Basel) ; 13(17)2021 Sep 04.

Article en En | MEDLINE | ID: mdl-34503272

Palabras clave

CVA21; coxsackievirus; immunotherapy; oncolytic virus; picornavirus; virotherapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google